Tofacitinib Global Market Opportunities And Strategies To 2032

Tofacitinib Market 2023 – By Drug Class (Antirheumatic, Janus kinase inhibitor, Immunosuppressant), By Dosage Strength (5mg, 10mg, 11mg, 22mg), By Indication (Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Other Indications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), And By Region, Opportunities And Strategies – Global Forecast To 2032

Starting Price : $5000.00 | Pages : 244 | Published : March 2024 | | Format : pdf

Purchase Options
Request Sample
Request For Discount

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Tofacitinib Market Definition

The tofacitinib market consists of sales of tofacitinib medication by entities (organizations, sole traders and partnerships) that produce and sell tofacitinib containing medications that are used alone or with other medications to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis in adults who are unable to take or do not respond to other medications.  

The tofacitinib is administered as a long-term treatment, with most patients that benefit from this treatment, noticing improvement within 12 weeks of starting treatment. Tofacitinib is associated with common side effects, including headaches, diarrhea and feeling sick. Rarely, it can cause more serious adverse events including leukopenia and an increased risk of serious infections, pulmonary embolism, lymphoma and other types of cancers.

Tofacitinib Market Size

The global tofacitinib market reached a value of nearly $1,822.84 million in 2022, having grown at a compound annual growth rate (CAGR) of 6.31% since 2017. The market is expected to grow from $1,822.84 million in 2022 to $2,156.20 million in 2027 at a rate of 3.42%. The market is then expected to grow at a CAGR of 4.82% from 2027 and reach $2,727.96 million in 2032.

Growth in the market resulted from growing cases of arthritis, the rise in government initiative for drug development, the increasing healthcare expenditure and the increasing size of the aging population. Factors that negatively affected growth in the historic period were stringent regulations on drug manufacturing and approval and high cost of tofacitinib drugs.

Tofacitinib Market Drivers

The key drivers of the tofacitinib market include:

Growing Cases Of Arthritis

The growing cases of arthritis drove the growth of the tofacitinib market during the historic period. Rheumatoid arthritis refers to an autoimmune and inflammatory condition where the immune system knowingly harms healthy cells in the body, leading to inflammation (painful swelling) in the body areas affected. Tofacitinib drugs are used to effectively reduce pain, enhance joint flexibility and inhibit the spread of arthritis. In November 2021, according to the Centers for Disease Control and Prevention, a US-based health protection agency, in the United States, there were 54.4 million adult-aged people diagnosed with arthritis as compared to 52.3 million in 2020.  Also, in February 2022, according to the National Arthritis Data Workgroup, a US-based consortium of experts in epidemiology, over 52.5 million adult Americans, or more than 22% of the population, had been diagnosed with arthritis or another rheumatic disease. Adults aged 18 and older with arthritis are predicted to reach 67 million by 2030.   Therefore, the rise in the prevalence of rheumatoid arthritis contributed to the growth of the tofacitinib market in the historic period and will als0 support the market growth during the forecast period.

Tofacitinib Market Restraints

The key restraints on the tofacitinib market include:

Stringent Regulations On Drug Manufacturing And Approval

The stringent regulations on drug manufacturing and approval limited the growth of the tofacitinib market during the historic period. Drug approval is subject to strict regulatory standards, particularly in terms of safety and efficacy. The time and money required to meet these regulatory requirements and get permits may delay market entry and limit the market growth. For drugs like tofacitinib used in the treatment of rheumatoid arthritis, adherence to high-quality standards is essential to guarantee that patients receive a product that meets established safety and effectiveness criteria. For example, the US Food and Drug Administration (FDA) ensures the quality of drug products by carefully monitoring drug manufacturers' compliance with its Current Good Manufacturing Practice (CGMP) regulations. These regulations provide the minimum requirements for the methods, facilities and controls used in manufacturing, processing and packing of a drug product. The CGMP regulations are designed to ensure that a product is safe for use and that it has the ingredients and strength it claims to have.  For example, in September 2019, the UK government introduced a restricted approval system under Article 14-3 of the Law on securing quality, efficacy and safety of pharmaceuticals, medical devices, regenerative and cellular therapy products, gene therapy products and cosmetics.  The potential loss of revenue due to delays and additional costs incurred due to stringent approval processes put a strain on investments relating to new drug development. Therefore, the stringent regulations on drug manufacturing and approval will restrict the growth of the tofacitinib market in future.

Tofacitinib Market Trends

Major trends shaping the tofacitinib market include:

Development Of Advanced Products Such As Tofacitinib Ointment To Treat Rheumatoid Arthritis

Companies operating in the tofacitinib market are focusing on developing and introducing advanced tofacitinib products such as tofacitinib ointment into the market to treat rheumatoid arthritis. For example, in June 2023, Intas Pharmaceuticals Ltd., an India-based pharmaceutical company, launched TOFATAS, a Drug Controller General of India (DCGI)-approved Tofacitinib Ointment 2% w/w. This product is specifically designed for the treatment of mild to moderate atopic dermatitis (AD) in patients aged 18 years and older experiencing flare-ups of the disease. This new treatment option aims to address the unmet needs in the management of atopic dermatitis, as approximately 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis has been introduced in India.

Focus on Getting Approval Of Tofacitinib In New Geographies

Tofacitinib drug manufacturers are focusing on gaining approval for various indications in new territories. For example, in March 2023, Zydus Lifesciences Ltd, an India-based pharmaceutical company, received final and tentative approval from the United States Food and Drug Administration (US FDA) for their generic Tofacitinib tablets, 5 mg and 10 mg.  The approval covers use for the treatment of adults with active psoriatic arthritis, moderately to severely active rheumatoid arthritis and patients with moderately to severely active ulcerative colitis. Further, in November 2021, Pfizer, a US-based pharmaceutical and biotechnology corporation, announced that the European Commission approved Xeljanz (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy

Opportunities And Recommendations In The Tofacitinib Market

Opportunities – The top opportunities in the tofacitinib market segmented by drug class will arise in the janus kinase inhibitor segment, which will gain $288.00 million of global annual sales by 2027. The top opportunities in the tofacitinib market segmented by dosage strength will arise in the 5mg segment, which will gain $201.42 million of global annual sales by 2027. The top opportunities in the tofacitinib market segmented by indication will arise in the rheumatoid arthritis segment, which will gain $166.71 million of global annual sales by 2027. The top opportunities in the tofacitinib market segmented by distribution channel will arise in the hospital pharmacy segment, which will gain $146.84 million of global annual sales by 2027. The tofacitinib market size will gain the most in the USA at $214.03 million.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the tofacitinib companies to focus on development of advanced products such as tofacitinib ointment to treat rheumatoid arthritis, focus on receiving approvals for new tofacitinib drugs, focus on generic drug launches to provide affordable treatment, focus on fast-growing drug classes, focus on tofacitinib medication with lower dosage strengths, expand in emerging markets, continue to focus on developed markets, focus on fast-growing distribution channels, provide competitively priced offerings in low-income countries, participate in trade shows and events, continue to use B2B promotions, target aging populations and  focus on patients with fast-growing indications.

Tofacitinib Market Segmentation

The tofacitinib market is segmented by drug class, by dosage strength, by indication and by distribution channel.

By Drug Class –
The tofacitinib market is segmented by drug class into:
    • a) Antirheumatic
    • b) Janus kinase inhibitor
    • c) Immunosuppressant
The janus kinase inhibitor market was the largest segment of the tofacitinib market segmented by drug class, accounting for 80.4% or $1,466.17 million of the total in 2022. Going forward, it is expected to be the fastest growing segment in the tofacitinib market segmented by drug class, at a CAGR of 3.65%.

By Dosage Strength –
The tofacitinib market is segmented by dosage strength into:
    • a) 5mg
    • b) 10mg
    • c) 11mg
    • d) 22mg
The 5mg market was the largest segment of the tofacitinib market segmented by dosage strength, accounting for 57.6% or $1,050.12 million of the total in 2022. Going forward, it is expected to be the fastest growing segment in the tofacitinib market segmented by dosage strength, at a CAGR of 3.57%.

By Indication –
The tofacitinib market is segmented by indication into:
    • a) Ulcerative Colitis
    • b) Rheumatoid Arthritis
    • c) Psoriasis
    • d) Other Indications
The rheumatoid arthritis market was the largest segment of the tofacitinib market segmented by indication, accounting for 53.2% or $969.53 million of the total in 2022. Going forward, the ulcerative colitis segment is expected to be the fastest growing segment in the tofacitinib market segmented by indication, at a CAGR of 3.44%.

By Distribution Channel –
The tofacitinib market is segmented by distribution channel into:
    • a) Hospital Pharmacy
    • b) Retail Pharmacy
    • c) Online Pharmacy
The hospital pharmacy market was the largest segment of the tofacitinib market segmented by distribution channel, accounting for 52.0% or $948.70 million of the total in 2022. Going forward, the online pharmacy segment is expected to be the fastest growing segment in the tofacitinib market segmented by distribution channel, at a CAGR of 4.5

By Geography - The tofacitinib market is segmented by geography into:
      o Asia Pacific
      • • China
      • • India
      • • Japan
      • • Australia
      • • Indonesia
      • • South Korea
      o North America
      • • USA
      o South America
      • • Brazil
      o Western Europe
      • • France
      • • Germany
      • • UK
      o Eastern Europe
      • • Russia
      o Middle East
      o Africa
North America was the largest region in the tofacitinib market, accounting for 64.4% or $1,174.49 million of the total in 2022. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the tofacitinib market will be Asia Pacific and North America where growth will be at CAGRs of 3.82% and 3.48% respectively. These will be followed by Western Europe and Eastern Europe where the markets are expected to grow at CAGRs of 3.11% and 1.51% respectively.

Tofacitinib Market Competitive Landscape

Major Competitors are:

  • Pfizer Inc
  • Beacon Pharmaceuticals PLC
  • Pharmascience Inc.
  • Qilu Pharmaceutical Co., Ltd
  • Delta Pharma Limited

    • Other Competitors Include:

  • Drug International Limited
  • Globe Group
  • Zydus Lifesciences Ltd.
  • Unichem Laboratories
  • Aprazer Healthcare Pvt Ltd
  • Apino pharma Co Ltd.
  • Shandong Octagon Chemicals Limited
  • Beijing Mesochem Technology Co. Ltd.
  • Esteve Pharmaceuticals SA
  • PSK Pharma
  • Eli Lilly and Company (API manufacturer)
  • Concert Pharmaceuticals, Inc.

      • Table Of Contents

      1Executive Summary

      1.1Tofacitinib – Market Attractiveness And Macro economic Landscape

      2Table Of Contents

      3List Of Tables

      4List Of Figures

      5Report Structure

      6Market Characteristics

      6.1General Market Definition

      6.2Summary

      6.3Tofacitinib Market Definition And Segmentations

      6.4Market Segmentation By Drug Class

      6.4.1Antirheumatic

      6.4.2Janus Kinase Inhibitor

      6.4.3Immunosuppressant

      6.5Market Segmentation By Dosage Strength

      6.5.15mg

      6.5.210mg

      6.5.311mg

      6.5.422mg

      6.6Market Segmentation By Indication

      6.6.1Ulcerative Colitis

      6.6.2Rheumatoid Arthritis

      6.6.3Psoriasis

      6.6.4Other Indications

      6.7Market Segmentation By Distribution Channel

      6.7.1Hospital Pharmacy

      6.7.2Retail Pharmacy

      6.7.3Online Pharmacy

      7Major Market Trends

      7.1Development Of Advanced Products Such As Tofacitinib Ointment To Treat Rheumatoid Arthritis

      7.2Focus on Getting Approval Of Tofacitinib In New Geographies

      7.3Increase In Generic Drug Launches To Provide Affordable Treatment

      8Tofacitinib Market - Macro Economic Scenario

      8.1COVID-19 Impact On The Tofacitinib Market

      8.2Impact Of The War In Ukraine On The Tofacitinib Market

      8.3Impact Of High Inflation On The Tofacitinib Market

      9Global Market Size and Growth

      9.1Market Size

      9.2Historic Market Growth, 2017 – 2022, Value ($ Million)

      9.3Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)

      9.4Market Drivers

      9.5Market Restraints

      10Global Tofacitinib Market Segmentation

      10.1Global Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      10.2Global Tofacitinib Market, Segmentation By Dosage Strength, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      10.3Global Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      10.4Global Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      11Tofacitinib Market, Regional and Country Analysis

      11.1Global Tofacitinib Market, By Region, Historic and Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      11.2Global Tofacitinib Market, By Country, Historic and Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12Asia-Pacific Market

      12.1Summary

      12.1.1Market Overview

      12.1.2Region Information

      12.1.3Market Information

      12.1.4Background Information

      12.1.5Government Initiatives

      12.1.6Regulations

      12.1.7Regulatory Bodies

      12.1.8Major Associations

      12.1.9Taxes Levied

      12.1.10Corporate Tax Structure

      12.1.11Investments

      12.1.12Major Companies

      12.2Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.3Asia-Pacific Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.4Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.5Asia-Pacific Tofacitinib Market: Country Analysis

      12.6China Market

      12.7Summary

      12.7.1Market Overview

      12.7.2Country Information

      12.7.3Market Information

      12.7.4Background Information

      12.7.5Government Initiatives

      12.7.6Regulations

      12.7.7Regulatory Bodies

      12.7.8Major Associations

      12.7.9Taxes Levied

      12.7.10Corporate Tax Structure

      12.7.11Investments

      12.7.12Major Companies

      12.8China Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.9China Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.1China Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.11India Market

      12.12India Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.13India Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.14India Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.15Japan Market

      12.16Japan Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.17Japan Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.18Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.19Australia Market

      12.2Australia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.21Australia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.22Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.23Indonesia Market

      12.24Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.25Indonesia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.26Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.27South Korea Market

      12.28South Korea Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.29South Korea Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      12.3South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13Western Europe Market

      13.1Summary

      13.1.1Market Overview

      13.1.2Region Information

      13.1.3Market Information

      13.1.4Background Information

      13.1.5Government Initiatives

      13.1.6Regulations

      13.1.7Regulatory Bodies

      13.1.8Major Associations

      13.1.9Taxes Levied

      13.1.10Corporate tax structure

      13.1.11Investments

      13.1.12Major Companies

      13.2Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.3Western Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.4Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.5Western Europe Tofacitinib Market: Country Analysis

      13.6UK Market

      13.7UK Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.8UK Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.9UK Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.1Germany Market

      13.11Germany Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.12Germany Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.13Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.14France Market

      13.15France Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.16France Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      13.17France Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      14Eastern Europe Market

      14.1Summary

      14.1.1Market Overview

      14.1.2Region Information

      14.1.3Market Information

      14.1.4Background Information

      14.1.5Government Initiatives

      14.1.6Regulations

      14.1.7Regulatory Bodies

      14.1.8Major Associations

      14.1.9Taxes Levied

      14.1.10Corporate Tax Structure

      14.1.11Investments

      14.1.12Major Companies

      14.2Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      14.3Eastern Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      14.4Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      14.5Eastern Europe Tofacitinib Market: Country Analysis

      14.6Russia Market

      14.7Russia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      14.8Russia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      14.9Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      15North America Market

      15.1Summary

      15.1.1Market Overview

      15.1.2Region Information

      15.1.3Market Information

      15.1.4Background Information

      15.1.5Government Initiatives

      15.1.6Regulations

      15.1.7Regulatory Bodies

      15.1.8Major Associations

      15.1.9Taxes Levied

      15.1.10Corporate Tax Structure

      15.1.11Investments

      15.1.12Major Companies

      15.2North America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      15.3North America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      15.4North America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      15.5North America Tofacitinib Market: Country Analysis

      15.6USA Market

      15.7Summary

      15.7.1Market Overview

      15.7.2Country Information

      15.7.3Market Information

      15.7.4Background Information

      15.7.5Government Initiatives

      15.7.6Regulations

      15.7.7Regulatory Bodies

      15.7.8Major Associations

      15.7.9Taxes Levied

      15.7.10Corporate Tax Structure

      15.7.11Investments

      15.7.12Major Companies

      15.8USA Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      15.9USA Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      15.1USA Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      16South America Market

      16.1Summary

      16.1.1Market Overview

      16.1.2Region Information

      16.1.3Market Information

      16.1.4Background Information

      16.1.5Government Initiatives

      16.1.6Regulations

      16.1.7Regulatory Bodies

      16.1.8Major Associations

      16.1.9Taxes Levied

      16.1.10Corporate Tax Structure

      16.1.11Investments

      16.1.12Major Companies

      16.2South America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      16.3South America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      16.4South America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      16.5South America Tofacitinib Market: Country Analysis

      16.6Brazil Market

      16.7Brazil Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      16.8Brazil Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      16.9Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      17Middle East Market

      17.1Summary

      17.1.1Market Overview

      17.1.2Region Information

      17.1.3Market Information

      17.1.4Background Information

      17.1.5Government Initiatives

      17.1.6Regulations

      17.1.7Regulatory Bodies

      17.1.8Major Associations

      17.1.9Taxes Levied

      17.1.10Corporate Tax Structure

      17.1.11Investments

      17.1.12Major Companies

      17.2Middle East Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      17.3Middle East Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      17.4Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      18Africa Market

      18.1Summary

      18.1.1Market Overview

      18.1.2Region Information

      18.1.3Market Information

      18.1.4Background Information

      18.1.5Government Initiatives

      18.1.6Regulations

      18.1.7Regulatory Bodies

      18.1.8Major Associations

      18.1.9Taxes Levied

      18.1.10Corporate Tax Structure

      18.1.11Major Companies

      18.2Africa Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      18.3Africa Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      18.4Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)

      19Competitive Landscape and Company Profiles

      19.1Company Profiles

      19.2Pfizer Inc

      19.2.1Company Overview

      19.2.2Products And Services

      19.2.3Business Strategy

      19.2.4Financial Overview

      19.3Beacon Pharmaceuticals PLC

      19.3.1Company Overview

      19.3.2Products And Services

      19.3.3Business Strategy

      19.3.4Financial Overview

      19.4Pharmascience Inc.

      19.4.1Company Overview

      19.4.2Products And Services

      19.4.3Business Strategy

      19.4.4Financial Overview

      19.5Qilu Pharmaceutical Co., Ltd

      19.5.1Company Overview

      19.5.2Products And Services

      19.5.3Business Strategy

      19.5.4Financial Overview

      19.6Delta Pharma Limited

      19.6.1Company Overview

      19.6.2Products And Services

      19.6.3Financial Overview

      20Key Mergers And Acquisitions

      20.1Sun Pharma Acquired Concert Pharmaceuticals

      20.2GSK Acquired Sierra Oncology

      20.3Pfizer Acquired Arena Pharmaceuticals

      21Opportunities And Strategies

      21.1Global Tofacitinib Market In 2027 – Countries Offering Most New Opportunities

      21.2Global Tofacitinib Market In 2027 – Segments Offering Most New Opportunities

      21.3Global Tofacitinib Market In 2027 – Growth Strategies

      21.3.1Market Trend Based Strategies

      21.3.2Competitor Strategies

      22Tofacitinib Market, Conclusions And Recommendations

      22.1Conclusions

      22.2Recommendations

      22.2.1Product

      22.2.2Place

      22.2.3Price

      22.2.4Promotion

      22.2.5People

      23Appendix

      23.1Geographies Covered

      23.2Market Data Sources

      23.3Research Methodology

      23.4Currencies

      23.5The Business Research Company

      23.6Copyright and Disclaimer

    List Of Tables

      Table 1: Global Tofacitinib Market, Historic, 2017 – 2022, $ Million
    • Table 2: Global Tofacitinib Market, Forecast, 2022 – 2027, 2032F, $ Million
    • Table 3: Global Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 4: Global Tofacitinib Market, Segmentation By Dosage Strength, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 5: Global Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 6: Global Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 7: Global Tofacitinib Market, By Region, Historic and Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 8: Global Tofacitinib Market, By Country, Historic and Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 9: Asia-Pacific GDP Per Capita, By Country, 2017-2022, $
    • Table 10:  Asia-Pacific Population, By Country, 2017-2027, Millions
    • Table 11: Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 12: Asia-Pacific Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 13: Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 14: China GDP Per Capita, 2017-2022, $
    • Table 15:  China Population, 2017-2027, Millions
    • Table 16: China Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 17: China Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 18: China Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 19: India Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 20: India Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 21: India Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 22: Japan Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 23: Japan Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 24: Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 25: Australia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 26: Australia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 27: Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 28: Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 29: Indonesia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 30: Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 31: South Korea Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 32: South Korea Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 33: South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 34: Western Europe GDP Per Capita, By Country, 2017-2022, $
    • Table 35:  Western Europe Population, By Country, 2017-2027, Millions
    • Table 36: Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 37: Western Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 38: Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 39: UK Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 40: UK Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 41: UK Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 42: Germany Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 43: Germany Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 44: Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 45: France Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 46: France Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 47: France Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 48: Eastern Europe GDP Per Capita, By Country, 2017-2022, $
    • Table 49:  Eastern Europe Population, By Country, 2017-2027, Millions
    • Table 50: Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 51: Eastern Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 52: Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 53: Russia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 54: Russia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 55: Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 56: North America GDP Per Capita, By Country, 2017-2022, $
    • Table 57:  North America Population, By Country, 2017-2027, Millions
    • Table 58: North America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 59: North America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 60: North America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 61: USA GDP Per Capita, 2017-2022, $
    • Table 62:  USA Population, 2017-2027, Millions
    • Table 63: USA Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 64: USA Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 65: USA Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 66: South America GDP Per Capita, By Country, 2017-2022, $
    • Table 67:  South America Population, By Country, 2017-2027, Millions
    • Table 68: South America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 69: South America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 70: South America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 71: Brazil Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 72: Brazil Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 73: Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 74: Middle East GDP Per Capita, By Country, 2017-2022, $
    • Table 75:  Middle East Population, By Country, 2017-2027, Millions
    • Table 76: Middle East Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 77: Middle East Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 78: Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 79: Africa GDP Per Capita, By Country, 2017-2022, $
    • Table 80:  Asia-Pacific Population, By Country, 2017-2027, Millions
    • Table 81: Africa Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 82: Africa Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 83: Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Table 84: Global Tofacitinib Market, Key Competitor Estimated Market Shares, 2022, Percentage (%)
    • Table 85: Pfizer Inc – Financial Overview, 2018 – 2022, $ Billion
    • Table 86: Beacon Pharmaceuticals PLC – Financial Overview, 2018 – 2022, $ Billion
    • Table 87: Pharmascience Inc – Financial Overview, 2022, $ Million
    • Table 88: Qilu Pharmaceutical Co., Ltd – Financial Overview, 2022, $ Million
    • Table 89: Delta Pharma Limited – Financial Overview, 2018 – 2022, $ Billion
    • Table 90: Global Tofacitinib Market Size Gain ($ Million), 2022 – 2027, By Country
    • Table 91: Global Tofacitinib Market Size Gain ($ Million), Segmentation By Drug Class, 2022 – 2027
    • Table 92: Global Tofacitinib Market Size Gain ($ Million), Segmentation By Dosage Strength, 2022 – 2027
    • Table 93: Global Tofacitinib Market Size Gain ($ Million), Segmentation By Indication, 2022 – 2027
    • Table 94: Global Tofacitinib Market Size Gain ($ Million), Segmentation By Distribution Channel, 2022 – 2027
    • Table 95: Tofacitinib Market Data Sources

    List Of Figures

      Figure 1: Global Tofacitinib Market Segmentation By Drug Class
    • Figure 2: Global Tofacitinib Market Segmentation By Dosage Strength
    • Figure 3: Global Tofacitinib Market Segmentation By Indication
    • Figure 4: Global Tofacitinib Market Segmentation By Distribution Channel
    • Figure 5: Global Tofacitinib Market, Historic, 2017 – 2022, $ Million
    • Figure 6: Global Tofacitinib Market, Forecast, 2022 – 2027, 2032F, $ Million
    • Figure 7: Global Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 8: Global Tofacitinib Market, Segmentation By Dosage Strength, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 9: Global Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 10: Global Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 11: Global Tofacitinib Market, By Region, Historic and Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 12: Global Tofacitinib Market, By Country, Historic and Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 13: Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 14: Asia-Pacific Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 15: Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 16: China Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 17: China Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 18: China Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 19: India Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 20: India Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 21: India Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 22: Japan Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 23: Japan Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 24: Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 25: Australia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 26: Australia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 27: Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 28: Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 29: Indonesia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 30: Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 31: South Korea Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 32: South Korea Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 33: South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 34: Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 35: Western Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 36: Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 37: UK Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 38: UK Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 39: UK Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 40: Germany Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 41: Germany Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 42: Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 43: France Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 44: France Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 45: France Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 46: Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 47: Eastern Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 48: Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 49: Russia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 50: Russia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 51: Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 52: North America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 53: North America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 54: North America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 55: USA Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 56: USA Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 57: USA Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 58: South America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 59: South America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 60: South America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 61: Brazil Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 62: Brazil Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 63: Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 64: Middle East Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 65: Middle East Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 66: Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 67: Africa Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 68: Africa Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 69: Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
    • Figure 70: Pfizer Inc – Financial Overview, 2018 – 2022, $ Billion
    • Figure 71: Beacon Pharmaceuticals PLC – Financial Overview, 2018 – 2022, $ Billion
    • Figure 72: Delta Pharma Limited – Financial Overview, 2018 – 2022, $ Billion
    • Figure 73: Geographic Regions Covered
    Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
    Read More
    Global Gene Therapy Market 2022 – Market Opportunities And Strategies
    Read More
    The Microbiome Market Share, Market Size, And Growth Rate 2022
    Read More
    Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
    Read More
    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
    Read More
    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Other Oncology Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other Distribution Channels), By Route Of Administration (Oral, Parental, Other Route Of Administration), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2032
    View Report
    Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Enzymes Global Market Report 2024 – By Product Type (Asparaginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products), By Application (Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications), By End User (Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories) – Market Size, Trends, And Global Forecast 2024-2033
    View Report
    Protein Inhibitors Global Market Report 2024 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies ) – Market Size, Trends, And Global Forecast 2024-2033
    View Report
    Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033
    View Report
    Biosimilars Global Market Report 2024 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
    View Report